ADMA Biologics develops, manufactures and markets specialty plasma-derived biologics, with news centered on its immune globulin portfolio led by ASCENIV and BIVIGAM. Company updates commonly cover FDA label and post-marketing developments for ASCENIV, primary humoral immunodeficiency indications, product revenue trends, U.S. immune globulin market conditions, and distribution arrangements.
Recurring announcements also address plasma collection and biomanufacturing operations, commercial expansion, cash generation, share repurchases, capital-structure priorities and pipeline updates such as SG-001. ADMA's business updates link manufacturing yield, raw plasma supply, distributor inventory and product demand to its financial results.
ADMA Biologics (Nasdaq: ADMA) reported third-quarter 2026 revenue of $141.1 million, up 5% year over year, alongside higher earnings. GAAP net income rose 37% to $49.9 million, and basic earnings per share increased 47% to $0.22. ASCENIV revenue grew 31% to $124.7 million, while BIVIGAM revenue fell to $15.4 million from $23.8 million a year earlier. Gross margin reached 71%, versus 56%.
ADMA reiterated expected 2026 revenue of at least $530 million and raised expected adjusted net income to at least $180 million and adjusted EBITDA to at least $275 million. Third-quarter repurchases totaled 2.7 million shares. For investigational SG-001, ADMA plans to incorporate FDA feedback into its clinical protocol and prepare an investigational new drug application; acceptance of its proposed testing assay remains subject to validation. Nine-month revenue reached $380.0 million, up 2%.
ADMA Biologics (Nasdaq: ADMA) will report its third quarter 2026 financial results after U.S. financial markets close on November 4, 2026.
Management will host a live conference call and audio webcast that day at 4:30 p.m. ET to discuss the results and other company updates. An archived replay will be available under Events & Webcasts in the investor section of the company’s website.
ADMA Biologics (Nasdaq: ADMA) announced a peer-reviewed publication reporting results from its optimized intravenous immune globulin (IVIG) manufacturing process. The article in Frontiers in Cardiovascular Medicine covers analytical testing of three commercial-scale lots made using the FDA-licensed process. Evaluated impurities were at or below applicable quantification limits; testing detected no immunoglobulin aggregates or fragments. The process increased immunoglobulin yield while maintaining product quality.
No thromboembolic events, or blood-clot events, were reported for products made using the optimized process from July 1, 2025 through July 31, 2026. Evidence is limited by the three-lot sample and relatively short surveillance period. Spontaneous reporting can miss events and cannot establish absence of risk or a causal link to clinical outcomes. Thrombosis remains a labeled IVIG risk.
ADMA Biologics (Nasdaq: ADMA) reported 2Q 2026 total revenue of $124.4 million, up 2% year-over-year, driven by ASCENIV revenue of $102.9 million, up 24%, while BIVIGAM revenue was $19.4 million, down 49% year-over-year but improving sequentially. GAAP net income was $37.8 million and GAAP basic EPS was $0.17, increasing 11% and 17% year-over-year, respectively. Adjusted net income reached $39.0 million and adjusted EBITDA $61.8 million, up 8% and 22%. Gross margin expanded to 69% from 55%.
For the first half of 2026, revenue was $238.9 million, with ASCENIV up 26% and BIVIGAM down 51% year-over-year; gross margin reached 70%. ADMA reiterated its FY2026 guidance for revenue of $530–$560 million, adjusted net income of $170–$200 million and adjusted EBITDA of $265–$300 million. The company repurchased about 13.8 million shares (5.3% of outstanding) year-to-date and advanced its SG-001 program and ASCENIV real-world outcomes data.
ADMA Biologics (Nasdaq: ADMA) will report its second quarter 2026 financial results on August 5, 2026, after U.S. markets close. Management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss the results and provide company updates.
Participants must register in advance to receive dial-in details and a unique PIN. A replay will be available under “Events & Webcasts” in the investor section of ADMA’s website.
ADMA Biologics (Nasdaq: ADMA) reported 1Q 2026 results: $114.5M revenue (flat YoY), ASCENIV revenue $97.5M (+28% YoY), BIVIGAM $15.4M (-54% YoY). The company posted Adjusted Net Income $40.7M (+22% YoY), Adjusted EBITDA $59.7M (+24% YoY), and $58M cash from operations. ADMA updated FY2026 guidance to $530M–$560M revenue, withdrew long‑term guidance, and said market dislocation drove timing and inventory effects while ASCENIV demand remained strong.
ADMA Biologics (Nasdaq: ADMA) announced FDA approval (May 4, 2026) of a supplemental BLA for ASCENIV, expanding the primary humoral immunodeficiency (PI) indication to pediatric patients two years of age and older. The approval reflects the final pediatric assessment required as a post‑marketing commitment and revises ASCENIV prescribing information; the prior pediatric indication started at age 12.
The company said the expanded label enables treatment of younger PI and immune‑compromised patients and follows completion of the clinical program supporting the pediatric assessment.
ADMA Biologics (Nasdaq: ADMA) will report first quarter 2026 financial results on May 6, 2026 after U.S. market close. Management will host a live conference call and audio webcast on May 6 at 4:30 p.m. ET.
Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the investor website.
ADMA (Nasdaq: ADMA) issued a detailed rebuttal to a March 24, 2026 short report, calling key allegations about ASCENIV and related‑party dealings "false and misleading." The company says end‑user demand and utilization for ASCENIV are at record highs and provides distributor inventory and pull‑through data.
ADMA cites average distributor inventory as of Jan 5, 2026 (ASCENIV 128 days, BIVIGAM 129 days) and Mar 22, 2026 (ASCENIV 90 days, BIVIGAM 92 days), plus above‑safety‑stock coverage (ASCENIV 84 to 48 days; BIVIGAM 87 to 51 days). ADMA also reports unqualified audit opinions for FY2024 and FY2025 and says its prior auditor resigned in late 2024.
ADMA Biologics (Nasdaq: ADMA) responded on March 25, 2026 to a March 24, 2026 report by Culper Research that disclosed a short position in ADMA.
The company said the report relies on unidentified sources, contains misleading and inaccurate statements, and that ADMA and its board are reviewing the assertions while continuing to report results in accordance with SEC rules and U.S. GAAP.